Key points are not available for this paper at this time.
Glucagon-like peptide-1 receptor agonists are a critical therapy for obesity and several related gastrointestinal conditions. Gastroenterologists are uniquely positioned to optimize their use, manage adverse events, coordinate multidisciplinary care, and ensure safe and effective integration into practice.
Pomenti et al. (Tue,) studied this question.